Evolution in the Care of NSCLC: Keeping Pace With Today’s Best Practices

Evolution in the Care of NSCLC: Keeping Pace With Today’s Best Practices (June 2019)

Sunday, June 2, 2019 in Chicago, Illinois
Dinner -- Sheraton Grand Chicago, 6:30 PM CT
Sheraton Ballroom V (Ballroom Level)


6:30 PM - 7:00 PM Dinner and Registration

7:00 PM - 7:15 PM Welcome and IntroductionH. Jack West, MD (Program Director)

7:15 PM - 8:50 PM Panel Case Discussions Across Advanced NSCLCEdward S. Kim, MD, FACP; Zofia Piotrowska, MD, MHS; Suresh S. Ramalingam, MD; H. Jack West, MD

NSCLC Subtypes to be covered:

  • Stage III, unresectable
  • EGFR mutation positive
  • ALK translocation positive
  • High PD-L1 expression, nonsquamous
  • No PD-L1 expression, nonsquamous
  • Low PD-L1 expression, squamous

8:50 PM - 9:00 PM Final Panel Discussion and Audience Question and Answer Session


Program Director
Howard West, MD

Associate Clinical Professor
City of Hope Comprehensive Cancer Center
Duarte, California

Edward Kim, MD

Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Zofia Piotrowska, MD

Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Suresh Ramalingam, MD

Professor of Hematology and Medical Oncology
Roberto C. Goizueta Chair for Cancer Research
Division of Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in the treatment of patients with NSCLC.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with NSCLC.

Learning Objectives

  • Assess the appropriate molecular markers to guide clinical decisions for patients with advanced-stage NSCLC
  • Integrate into practice the available clinical evidence and expert recommendations after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Plan individualized treatment strategies for patients with NSCLC positive for EGFR mutations, ALK gene rearrangements, BRAF mutations, or high PD-L1 expression, taking into consideration the available data and consensus expert recommendations
  • Appropriately manage treatment-related adverse events associated with targeted agents and immune checkpoint inhibitors used in patients with advanced-stage NSCLC
  • Describe to colleagues the speed of evolution in best practices for the treatment of NSCLC and the need to routinely use resources such as guidelines and tools in selecting treatment


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.